Vasoreactivity of the culprit lesion in unstable angina

P Bogaty1, D Hackett, G Davies

  • 1Cardiovascular Research Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Circulation
|July 1, 1994
PubMed

Insights

The culprit lesion in unstable angina constricts significantly more than stable angina lesions during provocative testing. This abnormal vasoreactivity may mark or predispose to recurrent acute ischemia.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Ischemic Heart Disease

Background:

  • Abnormal vasoconstriction is implicated in acute coronary syndromes.
  • The vasoreactivity of unstable angina culprit lesions remains uninvestigated.
  • It is unknown if enhanced vasoreactivity extends beyond the culprit lesion.

Purpose of the Study:

  • To investigate the vasoreactivity of the culprit lesion in unstable angina.
  • To compare culprit lesion vasoreactivity with stable angina lesions.
  • To assess vasoreactivity in distal and uninvolved coronary arteries.

Main Methods:

  • Quantitative coronary angiography was used in seven unstable angina patients and seven stable angina controls.
  • Provocative stimuli included ergometric bicycle exercise and a cold pressor test.
  • Luminal diameter of culprit lesions, distal segments, and uninvolved arteries were measured.

Main Results:

  • The culprit lesion in unstable angina significantly constricted with exercise and cold pressor tests.
  • Culprit lesions reduced diameter from 1.41 mm to 1.09 mm with exercise (P=.001).
  • Stable angina control lesions showed no significant change in diameter with provocative stimuli.

Conclusions:

  • Unstable angina culprit lesions exhibit increased vasoreactivity compared to stable angina lesions.
  • No significant vasoreactivity was observed in uninvolved or distal coronary segments.
  • Abnormal vasoreactivity at the culprit lesion site may indicate or predispose to recurrent ischemia.
Abstract

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...